Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine abuse potential and use disorder
Yu Liu, Deyong Lin, Boliang Wu, et al.
Brain Research Bulletin (2016) Vol. 126, pp. 68-73
Open Access | Times Cited: 213

Showing 1-25 of 213 citing articles:

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study
Carla M. Canuso, Jaskaran Singh, Maggie Fedgchin, et al.
American Journal of Psychiatry (2018) Vol. 175, Iss. 7, pp. 620-630
Open Access | Times Cited: 586
Ketamine: 50 Years of Modulating the Mind
Linda Li, Phillip E. Vlisides
Frontiers in Human Neuroscience (2016) Vol. 10
Open Access | Times Cited: 316
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up
Natalie Gukasyan, Alan K. Davis, Frederick S. Barrett, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 2, pp. 151-158
Open Access | Times Cited: 296
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
CNS Drugs (2020) Vol. 34, Iss. 9, pp. 925-946
Open Access | Times Cited: 166
Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites
Chun Yang, Jianjun Yang, Ailin Luo, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 163
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 161
A historical review of antidepressant effects of ketamine and its enantiomers
Wei Yan, Lijia Chang, Kenji Hashimoto
Pharmacology Biochemistry and Behavior (2020) Vol. 190, pp. 172870-172870
Open Access | Times Cited: 140
Mechanisms of ketamine and its metabolites as antidepressants
Evan Hess, Lace M. Riggs, Michael Michaelides, et al.
Biochemical Pharmacology (2021) Vol. 197, pp. 114892-114892
Open Access | Times Cited: 116
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Kyle A. Brown, Todd D. Gould
Molecular Psychiatry (2024) Vol. 29, Iss. 4, pp. 1114-1127
Open Access | Times Cited: 16
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects
Helena D. Aicher, Michael J. Mueller, Dario A. Dornbierer, et al.
Frontiers in Psychiatry (2024) Vol. 14
Open Access | Times Cited: 16
Metabolism and metabolomics of ketamine: a toxicological approach
Ricardo Jorge Dinis‐Oliveira
Forensic Sciences Research (2017) Vol. 2, Iss. 1, pp. 2-10
Open Access | Times Cited: 134
Major depressive disorder: Validated treatments and future challenges
Rabie Karrouri, Zakaria Hammani, Roukaya Benjelloun, et al.
World Journal of Clinical Cases (2021) Vol. 9, Iss. 31, pp. 9350-9367
Open Access | Times Cited: 102
Agmatine: multifunctional arginine metabolite and magic bullet in clinical neuroscience?
Gregor Laube, Hans‐Gert Bernstein
Biochemical Journal (2017) Vol. 474, Iss. 15, pp. 2619-2640
Open Access | Times Cited: 90
A Systematic Review and Meta‐analysis of Ketamine as an Alternative to Opioids for Acute Pain in the Emergency Department
Nicholas Karlow, Charles H. Schlaepfer, C Stoll, et al.
Academic Emergency Medicine (2018) Vol. 25, Iss. 10, pp. 1086-1097
Open Access | Times Cited: 89
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression
Elia E. Acevedo-Diaz, Grace W. Cavanaugh, Dede Greenstein, et al.
Journal of Affective Disorders (2019) Vol. 263, pp. 568-575
Open Access | Times Cited: 81
Quercitrin Rapidly Alleviated Depression-like Behaviors in Lipopolysaccharide-Treated Mice: The Involvement of PI3K/AKT/NF-κB Signaling Suppression and CREB/BDNF Signaling Restoration in the Hippocampus
Yan Sun, Hailou Zhang, Zhangjie Wu, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 18, pp. 3387-3396
Closed Access | Times Cited: 80
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Kyle T. Greenway, Nicolas Garel, Lisa Jerome, et al.
Expert Review of Clinical Pharmacology (2020) Vol. 13, Iss. 6, pp. 655-670
Closed Access | Times Cited: 72
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Yating Wang, Xiaole Wang, Sitong Feng, et al.
Pharmacological Research (2021) Vol. 171, pp. 105761-105761
Closed Access | Times Cited: 56
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 32
Narrative Review: Low-Dose Ketamine for Pain Management
Alessandro Riccardi, Mario Guarino, Sossio Serra, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3256-3256
Open Access | Times Cited: 25
Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder
Chloe E. Page, C. Neill Epperson, Andrew M. Novick, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 12, pp. 3802-3813
Closed Access | Times Cited: 11
Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?
Laura Hondebrink, Anne Zwartsen, Remco H.S. Westerink
Pharmacology & Therapeutics (2017) Vol. 182, pp. 193-224
Open Access | Times Cited: 76
Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agents
Molly C. Kalmoe, Alvin M. Janski, Charles F. Zorumski, et al.
Journal of the Neurological Sciences (2020) Vol. 412, pp. 116778-116778
Open Access | Times Cited: 59
Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects
Bhuvi Sachdeva, Punya Sachdeva, Shampa Ghosh, et al.
Ibrain (2023) Vol. 9, Iss. 1, pp. 90-101
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top